Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label, Escalation and Expansion Study to Evaluate Dosimetry, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CEA-Pre-Targeted 212Pb Therapy in Participants With Metastatic Colorectal Cancer
Conditions
Interventions
SPLIT Abs
203Pb-DOTAM
+1 more
Locations
1
United States
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Start Date
April 21, 2026
Primary Completion Date
February 12, 2034
Completion Date
February 12, 2034
Last Updated
April 14, 2026
NCT07446322
NCT07228832
NCT04657068
NCT06625775
NCT06607458
NCT06820463
Reference Study ID Number: BP45930 https://forpatients.roche.com/
CONTACT
888-662-6728 (U.S. and Canada)global-roche-genentech-trials@gene.comLead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions